Annual Report & Accounts

The report describes BerGenBio's 2022 focus on bemcentinib for first-line STK11-mutated NSCLC and hospitalized COVID-19, alongside completed studies and an ongoing development program. Group revenue was NOK 389 thousand and year-end employment was 29 people. ESG disclosures cover materiality analysis, 54,63 tons CO2e of emissions dominated by business travel, and SDG-linked activity; the Board oversees ESG and two of five directors are women.